

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SAMSUNG BIOEPIS CO., LTD.
Petitioner,

v.

REGENERON PHARMACEUTICALS, INC.,
Patent Owner.

Patent No. 11,253,572

Inter Partes Review No. IPR2023-00884

**PATENT OWNER'S MOTION FOR *PRO HAC VICE* ADMISSION OF
DARALYN J. DURIE UNDER 37 C.F.R. § 42.10(c)**

I. Relief Requested

Pursuant to 37 C.F.R. § 42.10, Patent Owner Regeneron Pharmaceuticals, Inc., requests that the Board admit Daralyn J. Durie *pro hac vice* in this proceeding.

II. Statement of Facts Showing Good Cause for the Board to Recognize Counsel *Pro Hac Vice* During the Proceeding

In accordance with 37 C.F.R. § 42.10(c), the Board may recognize counsel *pro hac vice* during a proceeding, subject to the conditions set forth therein, and any others that the Board may impose. Patent Owner sets forth these facts in support of this motion:

1. The undersigned contacted counsel for Petitioner (Quinn Emanuel Urquhart & Sullivan LLP), who indicated that Petitioner did not plan to oppose Ms. Durie’s admission *pro hac vice*.
2. Lead counsel for Patent Owner, Regeneron Pharmaceuticals, Inc., Adam Brausa, and Backup counsel, Rebecca Weires are registered practitioners.
3. Daralyn J. Durie is an experienced litigator and has established familiarity with the subject matter at issue in this proceeding. Accompanying this motion is **Exhibit 2061**, the Declaration of Daralyn J. Durie in Support of this Motion for Admission *Pro Hac Vice* (“Durie Decl.”). In her declaration, Ms. Durie attests, among other things, that she is a member in good standing of the California Bar. Durie Decl. ¶¶ 1-2. Ms. Durie has never been subject to

suspensions or disbarments from practice, nor had applications for admission to practice denied, nor been subject to any sanctions or contempt citations by any court or administrative body. Durie Decl. ¶¶ 3-5.

4. Ms. Durie has over 16 years of experience litigating patent cases involving biotechnology. Durie Decl. ¶ 9. As is relevant to this matter, Ms. Durie has litigated a number of cases relating to methods of treatment using antibodies. *Id.* In addition, Ms. Durie's familiarity with the subject matter at issue in this proceeding is demonstrated by her review of the '572 Patent, all cited prior art, and the IPR petition in this matter. Durie Decl. ¶ 10.

5. In her declaration, Ms. Durie also attests to her admission to practice in other courts, as well as each of the required items set forth by 37 C.F.R. §42.10(c) and *Unified Patents, Inc. v. Parallel Iron, LLC*, IPR2013-00639, Paper 7 (PTAB Oct. 15, 2013). *See* Durie Decl. ¶¶ 1-10.

III. Conclusion

For the foregoing reasons, Patent Owner respectfully request that the Board admit Daralyn J. Durie *pro hac vice* in this proceeding.

IPR2023-00884

Date: December 21, 2023

Respectfully Submitted,

By: /Adam R. Brausa/
Adam R. Brausa, Reg. No. 60,287
MORRISON & FOERSTER LLP
425 Market Street
San Francisco, California 94105
Tel: (415) 268-6053
ABrausa@mofo.com

Counsel for Patent Owner

Certificate of Service (37 C.F.R. § 42.6(e)(4))

I hereby certify that the attached PATENT OWNER'S MOTION FOR *PRO HAC VICE* ADMISSION OF DARALYN J. DURIE UNDER 37 C.F.R. § 42.10(c) and THE SUPPORTING DECLARATION OF DARALYN J. DURIE, were served on the date listed below via email (by agreement) upon the following counsel of record for Petitioner:

Raymond N. Nimrod (Reg. No. 31,987)
Matthew A. Traupman (Reg. No. 50,832)
Landon Andrew Smith (Reg. No. 79,248)
QUINN EMANUEL URQUHART
& SULLIVAN, LLP
51 Madison Ave., 22nd Floor
New York, NY 10010
Email: raynimrod@quinnemanuel.com
Email: matthewtraupman@quinnemanuel.com
Email: landonsmith@quinnemanuel.com
Email: qe-samsungbioepis@quinnemanuel.com

Dated: December 21, 2023

/Adam R. Brausa/
Adam R. Brausa, Reg. No. 60,287